EW vs. SYK, BSX, MDT, BDX, IDXX, RMD, DXCM, STE, HOLX, and BAX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.
Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
In the previous week, Edwards Lifesciences had 62 more articles in the media than Stryker. MarketBeat recorded 70 mentions for Edwards Lifesciences and 8 mentions for Stryker. Edwards Lifesciences' average media sentiment score of 0.87 beat Stryker's score of -0.18 indicating that Stryker is being referred to more favorably in the media.
Edwards Lifesciences received 427 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 71.48% of users gave Edwards Lifesciences an outperform vote while only 64.46% of users gave Stryker an outperform vote.
Stryker has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Stryker has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
77.1% of Stryker shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 5.9% of Stryker shares are owned by company insiders. Comparatively, 1.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Edwards Lifesciences has a net margin of 24.55% compared to Edwards Lifesciences' net margin of 16.03%. Edwards Lifesciences' return on equity of 23.05% beat Stryker's return on equity.
Stryker currently has a consensus target price of $372.05, suggesting a potential upside of 12.18%. Edwards Lifesciences has a consensus target price of $82.10, suggesting a potential upside of 31.63%. Given Stryker's higher probable upside, analysts clearly believe Edwards Lifesciences is more favorable than Stryker.
Summary
Stryker and Edwards Lifesciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
Free EW Stock Alerts